Serotonin research: contributions to understanding psychoses
Open accessAbstract
The history of serotonin research is closely related to the study of hallucinogenic drugs that function as agonists at serotonin-2A receptors. The fundamental idea that psychotic states seen in psychiatric disorders such as schizophrenia might be attributable, in part, to abnormalities in serotonergic systems began with the almost simultaneous discovery of lysergic acid diethylamide (LSD), psilocybin and serotonin. Sixty years of study have confirmed early speculations regarding the important relationship between serotonin and both drug-induced and disorder-based psychotic states. Now, modern biochemical, pharmacological, behavioral, neuroimaging, genetic and molecular biological sciences are converging to understand how serotonergic systems interact with other monoaminergic and glutamatergic systems to modulate states of consciousness and contribute to psychotic disorders such as the group of schizophrenias. This review summarizes experimental assessments of the serotonergic hallucinogen model psychosis in relation to the serotonin hypothesis of schizophrenia.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
LSD and other serotonergic hallucinogens induce profound visual hallucinations, altered sense of self and time, but no consistent delusions.
“Contrary to ketamine, LSD and other serotonergic hallucinogens induce profound visual hallucinations, together with altered sense of self and time 21 but no consistent delusions.22”
From Are hallucinations due to an imbalance between excitatory and inhibitory influences on the brain? (2016) · cites this paper as [21]
Cites
BRAFF, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,701 · see citing works
Self-citationDisorders of attention and perception in early schizophrenia
McGhie, A., & Chapman, J. (1961) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1961.tb00936.x · Cited by 1,195 · see citing works
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040 · see citing works
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · see citing works
Self-citationGonzález-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925 · see citing works
Identification of a serotonin/glutamate receptor complex implicated in psychosis
González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., et al. (2008) · Nature · doi:10.1038/nature06612 · Cited by 803 · see citing works
Neuropsychopharmacology : The Fifth Generation of Progress
Davis, K. L., Charney, D. S., Coyle, J. T., & Nemeroff, C. B. (2002) · Lippincott Williams & Wilkins eBooks · Cited by 747 · see citing works
The Early Symptoms of Schizophrenia
Chapman, J. (1966) · British Journal of Psychiatry · doi:10.1192/bjp.112.484.225 · Cited by 675 · see citing works
The Role of Serotonin in Antipsychotic Drug Action
Meltzer, H. M. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00046-9 · Cited by 664 · see citing works
The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans
Dittrich, A. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979351 · Cited by 577 · see citing works
Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451 · see citing works
Naturalizing consciousness: a theoretical framework.
Edelman, G. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931349100 · Cited by 440 · see citing works
Ketamine activates psychosis and alters limbic blood flow in schizophrenia
Lahti, A. C., Holcomb, H. H., Medoff, D. R., & Tamminga, C. A. (1995) · Neuroreport · doi:10.1097/00001756-199504190-00011 · Cited by 434 · see citing works
Startle Habituation and Sensorimotor Gating in Schizophrenia and Related Animal Models
Geyer, M. A., & BRAFF, D. L. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.4.643 · Cited by 411 · see citing works
Self-citationAghajanian, G. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00135-3 · Cited by 371 · see citing works
A systems model of altered consciousness: integrating natural and drug-induced psychoses
Vollenweider, F. X., & Geyer, M. A. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00646-3 · Cited by 339 · see citing works
Self-citationDRUGS WHICH ANTAGONIZE 5‐HYDROXYTRYPTAMINE
Gaddum, J. H., & Hameed, K. A. (1954) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1954.tb00848.x · Cited by 295 · see citing works
Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia
Ludewig, K., Geyer, M. A., & Vollenweider, F. X. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01925-x · Cited by 240 · see citing works
Self-citationSERUM VASOCONSTRICTOR (SEROTONIN)
Rapport, M. M., Green, A. A., & Page, I. H. (1948) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)57136-2 · Cited by 225 · see citing works
Gouzoulis-Mayfrank, E. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00089-x · Cited by 219 · see citing works
Serotonergic basis of antipsychotic drug effects in schizophrenia
Lieberman, J. A., Mailman, R. B., Duncan, G., Sikich, L., Chakos, M., Nichols, D. E., & Kraus, J. E. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00187-5 · Cited by 206 · see citing works
5-Hydroxytryptamine2A Receptor Inverse Agonists as Antipsychotics
Weiner, D. M., Burstein, E. S., Nash, N., Croston, G. E., Currier, E. A., Vanover, K. E., Harvey, S. C., Donohue, E., Hansen, H. C., Andersson, C. M., et al. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29327-7 · Cited by 203 · see citing works
Self-citationThe Neurochemical Circuitry of Schizophrenia
Carlsson, A. (2006) · Pharmacopsychiatry · doi:10.1055/s-2006-931483 · Cited by 199 · see citing works
Some Neurophysiological Aspects of Serotonin
Woolley, D. W., & Shaw, E. (1954) · BMJ · doi:10.1136/bmj.2.4880.122 · Cited by 188 · see citing works
Hallucinations. Behavior, Experience, and Theory.
(1976) · Annals of Internal Medicine · doi:10.7326/0003-4819-84-4-511_2 · Cited by 185 · see citing works
"Psychedelic" Experiences in Acute Psychoses
Bowers, M. B. (1966) · Archives of General Psychiatry · doi:10.1001/archpsyc.1966.01730150016003 · Cited by 183 · see citing works
The pipeline and future of drug development in schizophrenia
Gray, J. A., & Roth, B. L. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002062 · Cited by 181 · see citing works
Sabri, O., Erkwoh, R., Schreckenberger, M., Owega, A., Saß, H., & Buell, U. (1997) · The Lancet · doi:10.1016/s0140-6736(96)08380-8 · Cited by 165 · see citing works
Vollenweider, F., Csomor, P., Knappe, B., Geyer, M., & Quednow, B. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301324 · Cited by 159 · see citing works
Self-citationBenneyworth, M. A., Xiang, Z., Smith, R. L., Garcia, E. E., Conn, P. J., & Sanders‐Bush, E. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.035170 · Cited by 159 · see citing works
Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans
Carter, O. L., Hasler, F., Pettigrew, J. D., Wallis, G. M., Liu, G. B., & Vollenweider, F. X. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0930-9 · Cited by 146 · see citing works
Self-citationKonstitutionsaufklärung und Synthese von Psilocybin
Hofmann, A. A., Frey, A., Ott, H., Petrzilka, T., & Troxler, F. (1958) · Cellular and Molecular Life Sciences · doi:10.1007/bf02160424 · Cited by 140 · see citing works
Lahti, A. C., Weiler, M. A., Holcomb, H. H., Tamminga, C. A., Carpenter, W. T., & McMahon, R. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300837 · Cited by 133 · see citing works
Vollenweider, F. X. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979353 · Cited by 130 · see citing works
Self-citationEarly subjective experiences in schizophrenic episodes.
Freedman, B. J., & Chapman, L. J. (1973) · Journal of Abnormal Psychology · doi:10.1037/h0034952 · Cited by 130 · see citing works
Brain mechanisms of hallucinogens and entactogens
Vollenweider, F. X. (2001) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2001.3.4/fxvollenweider · Cited by 129 · see citing works
Self-citationDOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum
Sipes, T. E., & Geyer, M. A. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00316-8 · Cited by 118 · see citing works
Self-citationSymptom Differences in Schizophrenia with Good and Poor Prognosis
McCabe, M., Fowler, R. C., Cadoret, R. J., & Winokur, G. (1972) · American Journal of Psychiatry · doi:10.1176/ajp.128.10.1239 · Cited by 117 · see citing works
Ngan, E. T. C., Yatham, L. N., Ruth, T. J., & Liddle, P. F. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.1016 · Cited by 104 · see citing works
5-HT2A receptor density is decreased in the at-risk mental state
Hurlemann, R., Matusch, A., Kuhn, K.-U., Berning, J., Elmenhorst, D., Winz, O., Kölsch, H., Zilles, K., Wagner, M., Maier, W., et al. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0921-x · Cited by 98 · see citing works
Immediate effects of risperidone on cortico–striato–thalamic loops and the hippocampus
Liddle, P. F., Lane, C. J., & Ngan, E. T. C. (2000) · The British Journal of Psychiatry · doi:10.1192/bjp.177.5.402 · Cited by 96 · see citing works
Krebs-Thomson, K., Ruiz, E. M., Masten, V. L., Buell, M. R., & Geyer, M. A. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0566-1 · Cited by 95 · see citing works
Self-citationSome Serotoninlike Activities of Lysergic Acid Diethylamide
Shaw, E., & Woolley, D. W. (1956) · Science · doi:10.1126/science.124.3212.121 · Cited by 89 · see citing works
Behavioral Studies of Hallucinogenic Drugs in Animals: Implications for Schizophrenia Research
Geyer, M. A. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979350 · Cited by 80 · see citing works
Self-citationHollister, L. E., & Hartman, A. M. (1962) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(62)80024-8 · Cited by 73 · see citing works
Cohen, S. (1971) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7078-8_2 · Cited by 70 · see citing works
Gouzoulis‐Mayfrank, E., Habermeyer, E., Hermle, L., Steinmeyer, A., Kunert, H. J., & Sass, H. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80686-5 · Cited by 61 · see citing works
Sensorimotor Gating of Schizophrenia Patients Is Influenced by 5-HT2A Receptor Polymorphisms
Quednow, B. B., Kühn, K.-U., Mößner, R., Schwab, S. G., Schuhmacher, A., Maier, W., & Wagner, M. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.02.019 · Cited by 54 · see citing works
History, Rationale and Potential of Human Experimental Hallucinogenic Drug Research in Psychiatry
Gouzoulis‐Mayfrank, E., Hermle, L., Thelen, B., & Sass, H. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979348 · Cited by 50 · see citing works
5-HT2C Receptor Agonists as an Innovative Approach for Psychiatric Disorders
Rosenzweig-Lipson, S. J., Dunlop, J., & Marquis, K. L. (2007) · Drug News & Perspectives · doi:10.1358/dnp.2007.20.9.1162244 · Cited by 46 · see citing works
Blood Flow and Cerebral Laterality in the Mescaline Model of Psychosis
Hermle, L., Gouzoulis-Mayfrank, E., & Spitzer, M. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979352 · Cited by 44 · see citing works
Üçok, A., Alpsan, H., Çakır, S., & Saruhan‐Direskeneli, G. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30463 · Cited by 37 · see citing works
Geyer, M. A. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00123-2 · Cited by 28 · see citing works
Self-citationSimilarity of schizophrenia and the psilocybin syndrome as determined by objective methods.
Mh, K. (1965) · PubMed · Cited by 15 · see citing works
Halluzinogene — psychische grenzzustande in forschung und psychotherapie
Schultes, R. E. (1984) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(84)90023-0 · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762 · see citing works
REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180 · see citing works
Corticostriatal connectivity and its role in disease
Shepherd, G. M. G. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3469 · Cited by 824 · see citing works
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · see citing works
Self-citationPsychometric evaluation of the altered states of consciousness rating scale (OAV)
Studerus, E., Gamma, A., & Vollenweider, F. X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012412 · Cited by 683 · see citing works
Self-citationPsychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649 · see citing works
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
Vollenweider, F. X., & Preller, K. H. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0367-2 · Cited by 570 · see citing works
Self-citationStuderus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532 · see citing works
Self-citationSerotonin modulation of cortical neurons and networks
Celada, P., Puig, M. V., & Artigas, F. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00025 · Cited by 462 · see citing works
Toward a neurobiology of delusions
Corlett, P. R., Taylor, J. R., Wang, X.-J., Fletcher, P. C., & Krystal, J. H. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.007 · Cited by 394 · see citing works
From drugs to deprivation: A Bayesian framework for understanding models of psychosis
Corlett, P. R., Frith, C. D., & Fletcher, P. C. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1561-0 · Cited by 367 · see citing works
“LSD and other serotonergic hallucinogens induce profound visual hallucinations, together with altered experiences of time, space and the self (Geyer and Vollenweider 2008).”
BackgroundDrugs as instruments: A new framework for non-addictive psychoactive drug use
Müller, C. P., & Schumann, G. (2011) · Behavioral and Brain Sciences · doi:10.1017/s0140525x11000057 · Cited by 286 · see citing works
Psilocybin – Summary of knowledge and new perspectives
Tylš, F., Páleníček, T., & Horáček, J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.006 · Cited by 276 · see citing works
Designer drugs: mechanism of action and adverse effects
Luethi, D., & Liechti, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02693-7 · Cited by 262 · see citing works
Modern clinical research on LSD
Liechti, M. E. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.86 · Cited by 236 · see citing works
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232 · see citing works
Glutamatergic model psychoses: prediction error, learning, and inference
Corlett, P. R., Honey, G. D., Krystal, J. H., & Fletcher, P. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.163 · Cited by 229 · see citing works
Selvaraj, S., Arnone, D., Cappai, A., & Howes, O. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.06.005 · Cited by 223 · see citing works
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
van Elk, M., & Yaden, D. B. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104793 · Cited by 221 · see citing works
Diversity and plasticity of microglial cells in psychiatric and neurological disorders
Nakagawa, Y., & Chiba, K. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.010 · Cited by 208 · see citing works
Effect of Psilocybin on Empathy and Moral Decision-Making
Pokorny, T., Preller, K. H., Kometer, M., Dziobek, I., & Vollenweider, F. X. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx047 · Cited by 197 · see citing works
Self-citationAyahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
Kuypers, K. P. C., Riba, J., de la Fuente Revenga, M., Barker, S., Theunissen, E. L., & Ramaekers, J. G. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4377-8 · Cited by 201 · see citing works
Altered network hub connectivity after acute LSD administration
Müller, F., Dolder, P. C., Schmidt, A., Liechti, M. E., & Borgwardt, S. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.03.005 · Cited by 174 · see citing works
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 169 · see citing works
Are hallucinations due to an imbalance between excitatory and inhibitory influences on the brain?
Jardri, R., Hugdahl, K., Hughes, M., Brunelin, J., Waters, F., Alderson-Day, B., Smailes, D., Sterzer, P., Corlett, P. R., Leptourgos, P., et al. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw075 · Cited by 157 · see citing works
Timmermann, C., Bauer, P. R., Gosseries, O., Vanhaudenhuyse, A., Vollenweider, F., Laureys, S., Singer, T., Antonova, E., & Lutz, A. (2023) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2022.11.006 · Cited by 150 · see citing works
Self-citationNeural basis of psychosis-related behaviour in the infection model of schizophrenia
Meyer, U., & Feldon, J. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.12.022 · Cited by 158 · see citing works
Dimensions of consciousness and the psychedelic state
Bayne, T., & Carter, O. (2018) · Neuroscience of Consciousness · doi:10.1093/nc/niy008 · Cited by 142 · see citing works
Prediction error, ketamine and psychosis: An updated model
Corlett, P. R., Honey, G. D., & Fletcher, P. C. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116650087 · Cited by 142 · see citing works
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148 · see citing works
Correia, P. A., Lottem, E., Banerjee, D., Machado, A. S., Carey, M. R., & Mainen, Z. F. (2017) · eLife · doi:10.7554/elife.20975 · Cited by 138 · see citing works
dos Santos, R. G., Balthazar, F. M., Bouso, J. C., & Hallak, J. E. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116652578 · Cited by 125 · see citing works
Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments
Schmidt, A., Bachmann, R., Kometer, M., Csomor, P. A., Stephan, K. E., Seifritz, E., & Vollenweider, F. X. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.261 · Cited by 121 · see citing works
Reiche, S., Hermle, L., Gutwinski, S., Jungaberle, H., Gasser, P., & Majić, T. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.09.012 · Cited by 122 · see citing works
Serotonin and molecular neuroimaging in humans using PET
Saulin, A., Savli, M., & Lanzenberger, R. (2012) · Amino Acids · doi:10.1007/s00726-011-1078-9 · Cited by 113 · see citing works
Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain
Dean, J. G., Liu, T., Huff, S., Sheler, B., Barker, S. A., Strassman, R. J., Wang, M. M., & Borjigin, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-45812-w · Cited by 107 · see citing works
Tracing the development of psychosis and its prevention: what can be learned from animal models
Piontkewitz, Y., Arad, M., & Weiner, I. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.019 · Cited by 108 · see citing works
Mathai, D. S., Meyer, M. J., Storch, E. A., & Kosten, T. R. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.12.023 · Cited by 97 · see citing works
Bouso, J. C., Fábregas, J. M., Antonijoan, R. M., Rodríguez-Fornells, A., & Riba, J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3167-9 · Cited by 96 · see citing works
Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1772054 · Cited by 94 · see citing works
Preller, K. H., Schilbach, L., Pokorny, T., Flemming, J., Seifritz, E., & Vollenweider, F. X. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.1939-17.2018 · Cited by 71 · see citing works
Self-citationChronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia
Martin, D. A., Marona-Lewicka, D., Nichols, D. E., & Nichols, C. D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.03.013 · Cited by 67 · see citing works
Müller, F., Liechti, M. E., Lang, U. E., & Borgwardt, S. (2018) · Progress in Brain Research · doi:10.1016/bs.pbr.2018.08.004 · Cited by 31 · see citing works
Polito, V., Langdon, R., & Brown, J. (2010) · Consciousness and Cognition · doi:10.1016/j.concog.2010.05.013 · Cited by 31 · see citing works
Anxiolytic drug discovery: What are the novel approaches and how can we improve them?
Stewart, A. M., & Kalueff, A. V. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.857309 · Cited by 22 · see citing works
Barnett (2024) · doi:10.1089/psymed.2023.0010 · Cited by 13 · see citing works
Ching, T. H. W., Grazioplene, R., Pittenger, C., & Kelmendi, B. (2023) · doi:10.31234/osf.io/ba42z · Cited by 6 · see citing works
Tolerability, assessment, and prediction of psilocybin-induced altered states of consciousness
Studerus, E. (2012) · University of Zurich · doi:10.5167/uzh-164092 · Cited by 6 · see citing works
- Authors
- GEYER, M., & VOLLENWEIDER, F.
- Affiliations
- University of California San Diego (US)
- University of Zurich (CH)
- Corresponding author
- GEYER, M
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 29
- Issue
- 9
- Pages
- 445-453
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2155757287
- Cited by
- 427
- References
- 56
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 15 · 2023: 34 · 2022: 37 · 2021: 26 · 2020: 23 · 2019: 19 · 2018: 23 · 2017: 24 · 2016: 27 · 2015: 16 · 2014: 25 · 2013: 26 · 2012: 28
- FWCI
- 29.30
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Trends in Pharmacological Sciences (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- U.S. Department of Veterans Affairs
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- National Institute on Drug Abuse (DA 02925, R01DA002925)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- serotonin, 5-HT2A receptor, hallucinogens, LSD, psilocybin, schizophrenia, psychosis, serotonergic system, monoaminergic systems, glutamatergic system, states of consciousness, drug-induced psychosis
- MeSH terms
- Animals, Dose-Response Relationship, Drug, Hallucinogens, Humans, Psychoses, Substance-Induced, Psychotic Disorders, Serotonin, Serotonin Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
